FATE News and Press, Fate Therapeutics Inc. From 12/10/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Lone Pine Capital’s 13F portfolio value decreased from $31.03B to $29.68B. The number of positions increased from 36 to 39. They increased Twitter, Workday, and KE Holdings while dropping Global Payments and Mastercard. The top three positions are Shopify, Snap, and DoorDas...

SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event entitled &#...

Shares of Fate Therapeutics (FATE +13.0%) are up significantly today after Cowen initiated the company with an outperform rating. The firm does not have a price target. Analyst Tyler Van Buren writes that the company has a differentiated allogenic CAR T therapy approach that enhances current ...

Fate is doing excellent science. It is still valued at $4.58bn. I think that, in the absence of later-stage trial data, this stock is still somewhat overvalued. For further details see: Fate Therapeutics: Data Playing Catchup With Valuation

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q3-2021 13F filings the consensus holdings were updated, 5 stocks were removed and 5 added from the unive...

In this Motley Fool Live video recorded on Nov. 15 , Motley Fool contributors Keith Speights and Brian Orelli answer a viewer question about prospects for Fate Therapeutics (NASDAQ: FATE) , a stock favored by ARK Invest and its lead investor Cathie Wood. The company has seve...

GT Biopharma is an early-stage oncology company with one clinical asset. GT Biopharma will likely shift focus to their 2nd generation therapies, which are still preclinical. Lack of meaningful positive catalysts in the next year reduces attractiveness of investment. For furt...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated, 6 stocks were removed and 6 added from the univ...

Ahead of its data presentations in two major medical meetings in 2021, Citi has upgraded Fate Therapeutics (NASDAQ:FATE) to Buy from Neutral, citing over a 30% decline in its share price during the year. Today, the biotech announced that the Society for Immunotherapy of Cancer (SITC) Com...